The FDA has accepted a supplemental New Drug Application for TALZENNA in combination with XTANDI for metastatic castration-sensitive prostate cancer, supported by Phase 3 TALAPRO-3 trial data.

ClinicalJune 16, 2026

TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer

The Phase 3 TALAPRO-3 study demonstrated that TALZENNA plus XTANDI significantly improved radiographic progression-free survival (rPFS) by 52% in patients with HRR gene-altered metastatic prostate cancer.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

(1)

Topline Data

Pfizer — TALZENNA

June 16, 2026 · N/A

Indications

Prostate Cancer →

Therapeutic areas

Oncology →

Oncology · Prostate Cancer →

Prostate Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.